We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Regression of left ventricular hypertrophy after tafamidis therapy in a patient with transthyretin amyloidosis variant.
- Authors
Shusuke Yagi; Hiromu Yamazaki; Kenya Kusunose; Yusuke Osaki; Takayuki Ise; Muneyuki Kadota; Munkhtsetseg Tserensonom; Yutaka Kawabata; Tomoya Hara; Rie Ueno; Yoshihito Saijo; Tomomi Matsuura; Koji Yamaguchi; Hirotsugu Yamada; Daiju Fukuda; Takeshi Soeki; Tetsuzo Wakatsuki; Masataka Sata
- Abstract
Transthyretin amyloidosis (ATTR) variant is a life-threatening hereditary disease predominantly affecting the peripheral nervous system and heart. Tafamidis, which prevents the deposition of amyloid by stabilizing transthyretin, is available for the treatment of neuropathy and cardiomyopathy of ATTR. However, whether tafamidis could eliminate established amyloid deposits and improve cardiac function remains unknown. We reported a case of regression of left ventricular hypertrophy after tafamidis therapy in a patient with an ATTR variant. J. Med. Invest. 69: 320-322, August, 2022.
- Subjects
LEFT ventricular hypertrophy; TRANSTHYRETIN; AMYLOIDOSIS; NEUROPATHY; HEART function tests
- Publication
Journal of Medical Investigation, 2022, Vol 69, Issue 3/4, p320
- ISSN
1343-1420
- Publication type
Article
- DOI
10.2152/jmi.69.320